Injectable extended-release naltrexone for opioid dependence Reply

被引：1
|
作者：
Wolfe, Daniel [1 ]
Carrieri, M. P. [2 ,3 ,4 ]
Dasgupta, Nabarun [5 ]
Bruce, Douglas [6 ]
Wodak, Alex [7 ]
机构：
[1] Open Soc Fdn, Int Harm Reduct Dev Program, New York, NY 10019 USA
[2] INSERM, U912, SE4S, F-13258 Marseille, France
[3] Univ Aix Marseille, IRD, Marseille, France
[4] ORS PACA, Marseille, France
[5] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA
[6] Yale Univ, AIDS Programme, New Haven, CT USA
[7] St Vincents Hosp, Alcohol & Drug Serv, Darlinghurst, NSW 2010, Australia
来源：
LANCET | 2011年 / 378卷 / 9792期
关键词：
PHARMACOTHERAPIES;
D O I：
10.1016/S0140-6736(11)61333-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：666 / 666
页数：1
相关论文
共 50 条
  • [21] Impact on Counseling and Recovery Activities of Alcohol Dependence Treatment with Injectable Extended-Release Naltrexone
    Gromov, I.
    Kaempf, G.
    Silverman, B.
    Gastfriend, D. R.
    Cisler, R.
    SUBSTANCE ABUSE, 2009, 30 (02) : 192 - 193
  • [22] Reduced cigarette smoking during injectable extended-release naltrexone treatment for opioid use disorder
    Wang An-Li
    Shi Zhenhao
    Elman, Igor
    Langleben, Daniel D.
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2020, 46 (04): : 472 - 477
  • [23] Extended-release naltrexone for youth with opioid use disorder
    Mitchell, Shannon Gwin
    Monico, Laura B.
    Gryczynski, Jan
    Fishman, Marc J.
    O'Grady, Kevin E.
    Schwartz, Robert P.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2021, 130
  • [24] Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence A Randomized Clinical Noninferiority Trial
    Tanum, Lars
    Solli, Kristin Klemmetsby
    Latif, Zill-e-Huma
    Benth, Jurate Saltyte
    Opheim, Arild
    Sharma-Haase, Kamni
    Krajci, Peter
    Kunoe, Nikolaj
    JAMA PSYCHIATRY, 2017, 74 (12) : 1197 - 1205
  • [25] Effects of Injectable Extended-Release Naltrexone (XR-NTX) for Opioid Dependence on Residential Rehabilitation Outcomes and Early Follow-up
    Leslie, Douglas L.
    Milchak, William
    Gastfriend, David R.
    Herschman, Philip L.
    Bixler, Edward O.
    Velott, Diana L.
    Meyer, Roger E.
    AMERICAN JOURNAL ON ADDICTIONS, 2015, 24 (03): : 265 - 270
  • [26] Extended-release naltrexone overlooked in opioid use disorders guideline
    Rieb, Launette M.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2018, 190 (28) : E862 - E862
  • [27] Extended-release naltrexone opioid treatment at jail reentry (XOR)
    McDonald, Ryan D.
    Tofighi, Babak
    Laska, Eugene
    Goldfeld, Keith
    Bonilla, Wanda
    Flannery, Mara
    Santana-Correa, Nadina
    Johnson, Christopher W.
    Leibowitz, Neil
    Rotrosen, John
    Gourevitch, Marc N.
    Lee, Joshua D.
    CONTEMPORARY CLINICAL TRIALS, 2016, 49 : 57 - 64
  • [28] Naltrexone extended-release injection: an option for the management of opioid abuse
    Taylor, Robert, Jr.
    Raffa, Robert B.
    Pergolizzi, Joseph V., Jr.
    SUBSTANCE ABUSE AND REHABILITATION, 2011, 2 : 219 - 226
  • [29] Extended-release naltrexone for alcohol and opioid dependence: A meta-analysis of healthcare utilization studies
    Hartung, Daniel M.
    McCarty, Dennis
    Fu, Rongwei
    Wiest, Katharina
    Chalk, Mady
    Gastfriend, David R.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2014, 47 (02) : 113 - 121
  • [30] A Pilot Trial of Injectable, Extended-Release Naltrexone for the Treatment of Co-Occurring Cocaine and Alcohol Dependence
    Pettinati, Helen M.
    Kampman, Kyle M.
    Lynch, Kevin G.
    Dundon, William D.
    Mahoney, Elizabeth M.
    Wierzbicki, Michael R.
    O'Brien, Charles P.
    AMERICAN JOURNAL ON ADDICTIONS, 2014, 23 (06): : 591 - 597
12345